Light To Guide Our Feet
Light To Guide Our Feet

Menu

Collapse

Search Result

Collapse

Announcement

Collapse
No announcement yet.

What's Going On

Collapse

There are currently 129 users online. 32 members and 97 guests.

Most users ever online was 3,930 at 07:07 PM on 04-20-2019.

1 result in 0.0045 seconds.
Keywords
Members
Tags
l Trial x
  •  

  • Health and Human Services Funds Phase 2/3 Clinical Trial for Potential Treatment for COVID-19

    U.S. Department of Health and Human Services Funds Phase 2/3 Clinical Trial for Potential Treatment for COVID-19 | site |



    (March 21, 2020) - - Today (March 21, 2020), the U.S. Department of Health and Human Services (HHS) published the following information:

    An antibody medicine being evaluated to treat severe cases of coronavirus disease 2019 (COVID-19) will receive additional support from the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) under an existing partnership with Regeneron Pharmaceuticals of Tarrytown, New York.

    The Biomedical Advanced Research and Development Authority (BARDA) within ASPR will provide support for a U.S. Phase 2/3 clinical trial to evaluate Kevzara as a potential treatment for severely ill COVID-19 patients. Currently, Kevzara is approved by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis. Kevzara was developed
    ...
    See more | Go to post

Menu

Collapse

Trending

Collapse

  • Staff Reporter 1
    Health and Human Services Funds Phase 2/3 Clinical Trial for Potential Treatment for COVID-19
    by Staff Reporter 1
    U.S. Department of Health and Human Services Funds Phase 2/3 Clinical Trial for Potential Treatment for COVID-19 | site |



    (March 21, 2020) - - Today (March 21, 2020), the U.S. Department of Health and Human Services (HHS) published the following information:

    An antibody medicine being evaluated to treat severe cases of coronavirus disease 2019 (COVID-19) will receive additional support from the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) under an existing partnership with Regeneron Pharmaceuticals of Tarrytown, New York.

    The Biomedical Advanced Research and Development Authority (BARDA) within ASPR will provide support for a U.S. Phase 2/3 clinical trial to evaluate Kevzara as a potential treatment for severely ill COVID-19 patients. Currently, Kevzara is approved by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis. Kevzara was developed
    ...
    03-24-2020, 01:06 AM

Menu

Collapse

Menu

Collapse

Working...
X